Recursion Pharmaceuticals, Inc.
3.70USD
+0.1200 (+3.35%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on RXRX.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.23▲ | -$0.23 | 0 | 1 |
| Next quarter | -$0.22▼ | -$0.22 | 0 | 1 |
| Current year | -$0.93▼ | -$0.92 | 0 | 1 |
| Next year | -$0.87▲ | -$0.94 | 0 | 1 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.23 | -$0.25 | -0.02 (-6.8%) |
| 2026-03-31 | -$0.26 | -$0.22 | +0.04 (+14.4%) |
| 2025-12-31 | -$0.32 | -$0.21 | +0.11 (+33.3%) |
| 2025-09-30 | -$0.38 | -$0.36 | +0.02 (+5.7%) |
64 ratings from 11 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Needham | Reiterated | Buy | $8 | Oct 19, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $5 $5.5 | May 14, 2026 |
| Needham | Reiterated | Buy | $8 | May 7, 2026 |
| JP Morgan | Maintained | Overweight | $11 $10 | Apr 30, 2026 |
| B of A Securities | Maintained | Neutral | $7 $6 | Feb 26, 2026 |
| Needham | Reiterated | Buy | $8 | Feb 26, 2026 |
| JP Morgan | Upgraded from Neutral | Overweight | $10 $11 | Dec 17, 2025 |
| Needham | Reiterated | Buy | $8 | Sep 11, 2025 |
| Needham | Reiterated | Buy | $8 | Jul 8, 2025 |
| Morgan Stanley | Maintained | Equal-Weight | $8 $5 | Jun 16, 2025 |
| Needham | Maintained | Buy | $11 $8 | May 6, 2025 |
| Morgan Stanley | Maintained | Equal-Weight | $10 $8 | Apr 10, 2025 |
| Needham | Reiterated | Buy | $11 | Apr 8, 2025 |
| Leerink Partners | Maintained | Market Perform | $7 $6 | Feb 28, 2025 |
| Needham | Reiterated | Buy | $11 | Feb 6, 2025 |
| Keybanc | Maintained | Overweight | $12 $10 | Jan 8, 2025 |
| Needham | Reiterated | Buy | $11 | Dec 11, 2024 |
| Needham | Reiterated | Buy | $11 | Nov 20, 2024 |
| Needham | Reiterated | Buy | $11 | Nov 7, 2024 |
| Needham | Maintained | Buy | $16 $11 | Sep 4, 2024 |
| Jefferies | Maintained | Hold | $8 $6 | Sep 3, 2024 |
| Leerink Partners | Maintained | Market Perform | $9 $8 | Sep 3, 2024 |
| Needham | Maintained | Buy | $17 $16 | Aug 9, 2024 |
| Keybanc | Maintained | Overweight | $16 $12 | Jul 11, 2024 |
| Needham | Reiterated | Buy | $17 | Jun 25, 2024 |
159 filings from 19 insiders · 15 buy / 15 sell over 6m
Officers and directors of RXRX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Borgeson BlakeDirector | Sell | 50.0k | $4.84 | $242k | Oct 6, 2026 |
| HERSHBERG ROBERTDirector | ExerciseStock Option (Right to Buy) | 25.0k | $2.22 | $56k | Oct 6, 2026 |
| HERSHBERG ROBERTDirector | Sell | 25.0k | $5.00 | $125k | Oct 6, 2026 |
| HERSHBERG ROBERTDirector | Exercise | 25.0k | $2.22 | $56k | Oct 6, 2026 |
| Dar ZavainDirector | Grant | 4.6k | — | — | Oct 1, 2026 |
| Li Dean YDirector | Grant | 3.4k | — | — | Oct 1, 2026 |
| Taylor Ben ROfficer, Chief Financial Officer | Tax | 5.4k | $3.41 | $18k | Sep 15, 2026 |
| Khan NajatDirector; Officer, CEO and President | Sell | 22.4k | $3.52 | $79k | Sep 8, 2026 |
| Borgeson BlakeDirector | Sell | 30.0k | $3.34 | $100k | Sep 1, 2026 |
| BORGESON BLAKE CHARLESDirector | Sell | 30.0k | $3.25 | $98k | Aug 4, 2026 |
| BORGESON BLAKE CHARLESDirector | Sell | 40.0k | $3.96 | $159k | Jul 7, 2026 |
| LI DEAN YDirector | Grant | 3.7k | — | — | Jul 1, 2026 |
| DAR ZAVAINDirector | Grant | 5.1k | — | — | Jul 1, 2026 |
| BUMPUS NAMANDJE N.Director | Sell | 4.0k | $3.18 | $13k | Jun 18, 2026 |
| MICHOR FRANZISKA PH.D.Director | Grant | 88.4k | — | — | Jun 17, 2026 |
| BUMPUS NAMANDJE N.Director | Grant | 88.4k | — | — | Jun 17, 2026 |
| HERSHBERG ROBERT MDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
| SUN ELAINE DDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
| LI DEAN YDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
| BORGESON BLAKE CHARLESDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
No analyst notes on RXRX yet.
Analyst Ratings
6 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 1 | 4 | 0 | 0 | Buy2.29 |
| 1 mo ago | 2 | 1 | 4 | 0 | 0 | Buy2.29 |
| 2 mo ago | 2 | 1 | 4 | 0 | 0 | Buy2.29 |
| 3 mo ago | 2 | 1 | 4 | 0 | 0 | Buy2.29 |
Members whose judged calls on RXRX have played out most reliably.
No settled calls on RXRX yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice